Navigation Links
Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
Date:10/6/2008

dverse event (13.8% versus 16.0%).

-- Across the Contrave Phase 3 trial experience to date, only 7.6% of all reported adverse events led to an early discontinuation from the trials.

In summary, naltrexone SR met its primary objectives by providing a lower peak plasma concentration (Cmax) than the legacy IR formulation while retaining a similar total plasma exposure (AUC). This held true both for the parent molecule (naltrexone) and its principal active metabolite (6-beta-naltrexol). In a Phase I pilot study, improved tolerability was suggested amongst those who received naltrexone SR / bupropion SR than those receiving the prior Phase 2 formulation containing naltrexone IR. Finally, in a blinded, pooled analysis of preliminary Phase 3 data, results suggest that naltrexone SR / bupropion SR may be associated with decreased rates of treatment-emergent nausea, headache, dizziness, or discontinuation due to an adverse event.

About Orexigen(R) Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity and other central nervous system-related disorders. The Company's lead combination product candidates targeted for obesity are Contrave(R), which is in Phase 3 clinical trials, and Empatic(TM), which is in the later stages of Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Beyond obesity, Orexigen is developing drug combinations for use in schizophrenia and obsessive-compulsive disorder. Further information about the company can be found at http://www.Orexigen.com.

About Contrave(R)

Contrave is an investigational weight loss medication with a mechanism of action that works at two sites within the central nervous system. The first is a hypothalamic site that controls the balanc
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial on Schedule
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
4. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
7. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
8. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
9. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
10. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
11. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... , July 25, 2014  Depomed, Inc. (NASDAQ: ... second quarter fiscal year 2014 financial results after the ... host a conference call beginning at 4:30 pm EDT, 1:30 ... access the call by dialing 877-317-6789 ( United ... will also be available via a live webcast on ...
(Date:7/25/2014)... July 25, 2014 GrowBLOX Sciences, Inc. (OTCQB: GBLX) ... of Understanding ("MOU") with LaurelCo, LLC, an Illinois ... of both cultivation and dispensary medical marijuana licenses in the ... MOU, GBLX will acquire a 20% equity interest in LaurelCo, ... TM growing chambers, as well as all technology related ...
(Date:7/25/2014)... July 25, 2014 According to ... "Global and China Insulin Market (Rapid-Acting, Short-Acting, Intermediate-Acting, Long-Acting, ... Share, Growth, Trends and Forecast (Value and Volume), 2013 ... USD 19.99 billion in 2012 and is expected to ... 2019 to reach USD 32.24 billion in 2019. ...
Breaking Medicine Technology:Depomed To Report Second Quarter Fiscal Year 2014 Financial Results On Wednesday, August 6, 2014 2GrowBLOX Sciences, Inc. Partners with LaurelCo, LLC to Obtain Licenses to Cultivate and Dispense Medical Marijuana in Illinois 2GrowBLOX Sciences, Inc. Partners with LaurelCo, LLC to Obtain Licenses to Cultivate and Dispense Medical Marijuana in Illinois 3Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 2Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 3Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 4
... Helen Londe, M.D. Contributing Editor The first human case of ... occurred in Kansas in late June. The CDC has ... being 2005's first documented incidence of the mosquito borne disease ... about 11 kb. It primarily infects birds and mosquitoes, ...
... lipids, comprised of triglycerides and cholesterols, vary with genetic ... factors contribute to serum cholesterol and triglyceride levels and ... events. Perhaps no other commonly determined medical laboratory values ... levels of good, bad, and total cholesterol, making the ...
Cached Medicine Technology:West Nile Virus Screening and Diagnostics Technology Emerges In Step with North American Outbreak 2West Nile Virus Screening and Diagnostics Technology Emerges In Step with North American Outbreak 3West Nile Virus Screening and Diagnostics Technology Emerges In Step with North American Outbreak 4Analyzers Offer Point-of-Care Lipid Panels 2Analyzers Offer Point-of-Care Lipid Panels 3
(Date:7/28/2014)... (PRWEB) July 28, 2014 As health ... are looking to private exchanges. “Private Exchange Strategies ... 6 webinar from Atlantic Information Services, will provide answers ... exchange strategies for the future. , Barbara Gniewek, Jonathan ... with extensive experience in the private exchange sector — ...
(Date:7/28/2014)... According to the Heartburn No More PDF review recently ... help people get rid of acid reflux naturally. ... heartburn and acid reflux. In addition, inside this book, people ... factors for reflux disease. , Vkool informs in its ... symptoms of reflux disease naturally without medications. The book also ...
(Date:7/28/2014)... 28, 2014 Building a sense of ... important. Where personal outdoor space is not possible, ... enjoy fun and exercise outside is important. That’s ... in quality commercial playground equipment from APCPLAY. , Old ... Midlothian, Virginia. It is an historic tourist location of ...
(Date:7/28/2014)... Calif., July 27, 2014 - (PRWEB) July 28, 2014 ... in 12 months by earning the Masters Champion title at ... proving that age is no obstacle for this athlete. She ... at the event hosted by the International Pole Sports Federation ... 63, traveling from 30 countries, took part in the competition. ...
(Date:7/28/2014)... Dr. Alan Xenakis, MD announced today the ... Feelings.” The new book, DOC X MD Funny Feelings ... story telling style with humor and medical accuracy. The book ... will find answers to those age-old questions that most folks ... pee? Why do mosquitoes bite some and not others? Why ...
Breaking Medicine News(10 mins):Health News:Three PwC Consultants to Offer Insurers Successful Strategies for Private Exchanges 2Health News:Heartburn No More Pdf Review Exposes Jeff Martin's Guide For Treating Heartburn – Vkool.com 2Health News:Heartburn No More Pdf Review Exposes Jeff Martin's Guide For Treating Heartburn – Vkool.com 3Health News:Playground Creates Outdoor Fun for Community at Old Buckingham Station at Midlothian Village (VA) with APCPLAY© 2Health News:Inspiring Senior Athlete Lands Third World Title in One Year 2Health News:New Book by Alan P. Xenakis, MD Reveals Mind and Body Mysteries 2
... Texas Pesticides and pollutants are related to an alarming ... anencephaly in rural China, according to scientists at The University ... of the pesticides found in high concentrations in the placentas ... Endosulfan is only now being phased out in the United ...
... Steven Reinberg HealthDay Reporter , TUESDAY, Oct. ... friends tend to have areas of the brain that ... with fewer friends, British researchers say. "We were ... in them is reflected in brain structure and function," ...
... cardiac arrest is the leading cause of death in the ... initial collapse. In addition, fewer than half of the small ... the hospital, because they often suffer irreversible brain damage. A ... Neurology provides guidance to physicians using therapeutic cooling to ...
... flushes and night sweats years after the menopause finds a new ... and Gynaecology . Hot flushes and night sweats (HF/NS) are ... severity and duration vary considerably. The average age of ... it is generally assumed that HF/NS last between 2 to 5 ...
... Spanish . Researchers from Massachusetts General ... cell mechanism activated by a protein HOXB9 that becomes an ... world continue to focus their research on breast cancer. As ... growing, as well as of their interactions with the microenvironment. ...
... Duke University Medical Center researchers have verified data that ... a patient who has been under anesthesia for an operation. ... first year after surgery if a patient has low values ... patients whose values are all normal. The three ...
Cached Medicine News:Health News:Study links pollutants to a 450 percent increase in risk of birth defects 2Health News:Study links pollutants to a 450 percent increase in risk of birth defects 3Health News:More Facebook Friends, More Gray Matter in Brain? 2Health News:More Facebook Friends, More Gray Matter in Brain? 3Health News:Mayo Clinic study guides physicians using therapeutic cooling to treat cardiac arrest patients 2Health News:Older women still suffer from hot flushes and night sweats years after the menopause finds study 2Health News:Discovery of a cell mechanism that reduces effectiveness of breast cancer treatment 2Health News:3 factors could point to your fate after surgery 2
... The proper gel is essential ... when working with pH catheters ... specific chloride ion concentration in ... required for proper function of ...
The WaveMax is one of the most flexible stainless steel stents due to its unique wave design and has the lowest effective profile, accommodating a 6F sheath up to 7 mm....
... its specifically designed reagents, allows to ... sample, multiple analytes. This unique technology ... laboratories willing to simplify and standardize ... as well as to reduce as ...
... a variety of applications across a broad ... is suitable for any laboratory demanding high ... mixed-mode throughput exceeding 95 PT/aPTT/Fibrinogen per hour ... range of chromogenics, the AMAX DestinyPlus is ...
Medicine Products: